Peptide Atlas · Peptide
Davunetide
Davunetide (NAP, AL-108) is an intranasal peptide that stabilized microtubules and reduced tau phosphorylation in preclinical studies; in a 52-week phase 2/3 trial in 313 people with progressive supranuclear palsy it did not differ from placebo on either primary measure.
- established
- provisional
- 8 aa
- PubChem 9832404
- 2 citations
- 0 discussions
- 0 followers
- ADNF fragment
- AL-108
- AL-208
- NAP
- NAPVSIPQ
- activity-dependent neuroprotective protein fragment
What the evidence says
six tiers, never blendedestablished — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Negative findings
failure is informationNobody has filed a failure yet. Failures are information; this list is waiting for an honest one.